Plasminogen activator inhibitor type 2 in breast cancer.

[1]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  S. Brem,et al.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. , 1995, The Journal of clinical investigation.

[3]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[4]  B. Åstedt,et al.  Urokinase-producing Tumour Growth in SCID Mice Inhibited by Recombinant PAI-2 , 1995 .

[5]  J. Foekens,et al.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. , 1995, Cancer research.

[6]  A. Thor,et al.  Immunohistochemical localization of the plasminogen activator inhibitor‐1 in breast cancer , 1995, International journal of cancer.

[7]  W. Laug,et al.  Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Spyratos,et al.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. , 1994, British Journal of Cancer.

[10]  M. Duffy.  Urokinase-type plasminogen activator and malignancy , 1993 .

[11]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[12]  T. Urano,et al.  Plasminogen activator system in human breast cancer , 1992, International journal of cancer.

[13]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[14]  A. Desplaces,et al.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. , 1991, British Journal of Cancer.

[15]  M. Baker,et al.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. , 1990, Cancer research.

[16]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[17]  M. Duffy,et al.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer. , 1988, Cancer research.

[18]  T. Ny,et al.  The placental type plasminogen activator inhibitor, PAI 2 , 1987 .

[19]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[20]  W. Black,et al.  Benign Breast Tumours , 1950, Medicine illustrated.